Provided by Tiger Fintech (Singapore) Pte. Ltd.

Armata Pharmaceuticals, Inc.

2.54
+0.09003.67%
Post-market: 2.540.00000.00%16:56 EDT
Volume:2.25K
Turnover:5.53K
Market Cap:91.93M
PE:-2.34
High:2.54
Open:2.43
Low:2.43
Close:2.45
Loading ...

Armata Pharmaceuticals Inc. Conducted Annual Shareholders Meeting

Reuters
·
14 Jun

Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
20 May

HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating

MT Newswires Live
·
19 May

Armata reports data from Phase 1b/2a diSArm trial

TIPRANKS
·
19 May

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a diSArm Trial of AP-SA02 for Staphylococcus aureus Bacteremia

Reuters
·
19 May

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

Benzinga
·
15 May

Armata Pharmaceuticals Reports Q1 2025 Net Loss of $6.5M, Improvement from $25M Loss in 2024; EPS Loss Narrows to $0.18

Reuters
·
15 May

Armata Pharmaceuticals Secures Additional $4.65 Million Non-Dilutive Funding from U.S. Department of Defense to Support Ongoing Clinical Trial of AP-SA02

Reuters
·
01 May

Press Release: Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Dow Jones
·
01 May

New Strong Sell Stocks for April 24th

Zacks
·
24 Apr

New Strong Sell Stocks for April 9th

Zacks
·
09 Apr

Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate

Benzinga
·
21 Mar

BRIEF-Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update

Reuters
·
21 Mar

Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva

MT Newswires Live
·
13 Mar

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

PR Newswire
·
11 Mar